LIPOCINE INC.

377.4 USD (+4.11%)

04/10/2025 - 15:34 Closed 15 min delayed data - NASDAQ Stocks

Open:	390.0
Change:	+14.9
Volume:	5,025

Low:	377.1
High:	391.9
High / Low range:	14.8

Type:	Stocks
Ticker:	LPCN
ISIN:

LIPOCINE INC. news, videos and press releases

For more news please use our advanced search feature.
LIPOCINE INC. - More news...

Lastest news LIPOCINE INC.

03/26/2025 - 12:00 Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
03/13/2025 - 12:00 Lipocine Announces Financial Results for the Full Year Ended December 31, 2024
03/12/2025 - 12:00 Lipocine Announces FDA Labeling Changes for Testosterone Products
02/06/2025 - 13:00 Lipocine Receives Updated Regulatory Guidance on LPCN 1154
12/17/2024 - 13:00 FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
11/18/2024 - 13:00 Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
11/07/2024 - 13:00 Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024
10/31/2024 - 12:00 Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea
10/10/2024 - 12:00 Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
10/08/2024 - 12:00 Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
10/02/2024 - 12:00 Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
09/30/2024 - 12:00 Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference
09/05/2024 - 12:00 Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
08/27/2024 - 12:00 Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
08/08/2024 - 12:00 Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024
06/25/2024 - 12:00 Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
06/10/2024 - 12:00 Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024
05/09/2024 - 12:00 Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
05/08/2024 - 12:00 Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
05/01/2024 - 12:00 Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
04/11/2024 - 11:00 Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
03/28/2024 - 12:00 Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
03/25/2024 - 12:00 Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
03/07/2024 - 13:00 Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
03/06/2024 - 13:00 Lipocine to Present at 36th Annual Roth Conference
02/06/2024 - 13:00 Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
02/02/2024 - 13:00 Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
01/18/2024 - 13:00 Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
12/19/2023 - 13:00 Lipocine to Present at Biotech Showcase 2024
11/13/2023 - 19:45 Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023